A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer (RCC)

Inclusion Criteria:

- Male or female patients >/= 18 years of age.

- Patients, who suffer from unresectable and/or metastatic, measurable predominantly
clear cell RCC histologically or cytologically documented.

- Patients must be previously untreated for advanced disease. Prior palliative
radiation therapy is allowed if the target lesion(s) are not included within the
radiation field and no more than 30% of the bone marrow is irradiated.

- Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI
according to Response Evaluation Criteria in Solid Tumors (RECIST).

- Patients with "Intermediate" or "Low" risk per the Motzer score.

- Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of
0 or 1.

- Adequate bone marrow, renal and hepatic function as assessed by the following
laboratory requirements to be conducted within 7 days prior to study drug treatment

Exclusion Criteria:

- Patients who have received prior systemic treatment regimens for RCC.

- Uncontrolled/unstable cardiac disease

- Uncontrolled hypertension

- Active clinically serious infections (> CTCAE grade 2 )

- History of HIV infection or chronic hepatitis B or C.

- Known history or symptomatic metastatic brain or meningeal tumours

- Patients with seizure disorder requiring medication

- Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding
event >/= CTCAE Grade 3 within 4 weeks of first dose of study.

- Pregnant or breast-feeding patients